Search PubMed⌕ Search

Biomedical subjects

T Kusunoki

Publications and source records attributed to T Kusunoki.

At least 127 records · Page 7Linked to original sources

Mass screening of neuroblastoma in infancy.

A vanillylmandelic acid spot test for screening infants for neuroblastoma was developed in cooperation with 11 health centers in Kyoto, Japan. In this system, the parent sends a filter paper spotted with the infant's urine at 6 or 7 months of age. From 78,331 infants screened during the six years from July 1973 to September 1979, four asymptomatic infants with neuroblastoma were discovered. Three of them have already completed their treatments and have recovered. The cost of screening 13,000 infants per year was $7,500. One false-negative test was encountered, as were a number of false-positive tests.

Age Factors↗

Studies on 125I-alpha bungarotoxin binding sites in rat brain.

The distribution and properties of 125I-alpha bungarotoxin (125I-alpha BTX) binding in rat brain using micropunched tissue homogenates were examined with a binding technique. Highest level of 125I-alpha BTX binding was observed in the hypothalamus, followed by hippocampus, cortex, globus pallidus, nucleus caudatus and nucleus accumbens. Although high levels of 3H-quinuclidinyl benzilate (3H-QNB) binding in the striatum were found at dorso-lateral sites and low levels in the central regions, the level of 125I-alpha BTX binding within the striatum was almost equal. There was no significant correlation between 125I-alpha BTX binding and choline uptake which could be useful as a marker for functional cholinergic nerve terminals. The inhibition of specific 125I-alpha BTX binding to the hippocampal homogenates by nicotine, d-tubocurarine and other nicotine drugs was studied. The results of these studies suggest that alpha BTX binding sites in the brain are not likely the binding sites of nicotine or the physiological ACh R sites.

Animals↗

Effects of interferon on C1300 mouse neuroblastoma.

The effects of murine interferon (MuIFN) with and without cyclophosphamide (CY) were evaluated in C1300 neuroblastoma-bearing mice. Mean survival times were prolonged by administration of 25,000 IU of MuIFN three times per week by ip injection. The combination of MuIFN and CY was more effective in the treatment of mouse neuroblastoma than either agent alone. Our results suggested that MuIFN is synergistic in combination with moderate amounts of CY in mouse neuroblastoma cells and may be given for the treatment of neuroblastoma.

Animals↗

Effects of intralesional interferon on neuroblastoma: changes in histology and DNA content distribution of tumor masses.

Local injections of interferon, 30 X 10(4) IU, ten times, were found to reduce masses of neuroblastoma. Histologic findings and nuclear DNA measurements of cells from tumors in which interferon has been injected compared with cells from tumors that did not receive injections demonstrated that the reduction of neuroblastoma masses by interferon did not depend on increased cell differentiation or on interruption of tumor cell production. Although the mechanism of interferon's action on reducing neuroblastoma is unknown, the disappearance of tumor cells may be caused by high levels of interferon in tumor tissues.

Adult↗

[CT in normal pressure hydrocephalus--correlation between CT and clinical response to shunting (author's transl)].

CT scans were obtained on 33 patients (age 73y. to 31y.) with the diagnosis of normal pressure hydrocephalus. In each case, the diagnosis was made on the basis of the symptoms, CT and cisternographic findings. Underlying diseases of normal pressure hydrocephalus are ruptured aneurysms (21 cases), arteriovenous malformations (2 cases), head trauma (1 case), cerebrovascular accidents (1 case) and idiopathy (8 cases). Sixteen of 33 patients showed marked improvement, five, moderate or minimal improvement, and twelve, no change. The results were compared with CT findings and clinical response to shunting. CT findings were classified into five types, bases on the degree of periventricular hypodensity (P.V.H.), the extent of brain damage by underlying diseases, and the degree of cortical atrophy. In 17 cases of type (I), CT shows the presence of P.V.H. with or without minimal frontal lobe damage and no cortical atrophy. The good surgical improvements were achieved in all cases of type (I) by shunting. In 4 cases of type (II), CT shows the presence of P.V.H. and severe brain damage without cortical atrophy. The fair clinical improvements were achieved in 2 cases (50%) by shunting. In one case of type (III), CT shows the absence of P.V.H. without brain damage nor cortical atrophy. No clinical improvement was obtained by shunting in this type. In 9 cases of type (IV) with mild cortical atrophy, the fair clinical improvement was achieved in two cases (22%) and no improvement in 7 cases. In 2 cases of type (V) with moderate or marked cortical atrophy, no clinical improvement was obtained by shunting. In conclusion, it appeared from the present study that there was a good correlation between the result of shunting and the type of CT, and clinical response to shunting operation might be predicted by classification of CT findings.

Adult↗